Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide.

• Mazdutide treatment resulted in significant reductions in HbA1c compared to placebo, with all doses showing improvements (P < 0.0001).
• Body weight reductions with mazdutide were dose dependent, reaching up to -7.1%, while dulaglutide and placebo showed smaller changes.
• Participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% and ≤6.5% compared to those on placebo.
• Weight loss of ≥5% and ≥10% from baseline was more frequently observed in the mazdutide groups than in the placebo group.
• Common adverse events associated with mazdutide included diarrhea (36%), decreased appetite (29%), and nausea (23%).

AI simplified